Cardiac Arrest News and Research RSS Feed - Cardiac Arrest News and Research

A cardiac arrest, also known as cardiopulmonary arrest or circulatory arrest, is the abrupt cessation of normal circulation of the blood due to failure of the heart to contract effectively during systole.
Study: Around 6% survive cardiac arrest outside of hospital setting

Study: Around 6% survive cardiac arrest outside of hospital setting

Cardiac arrest strikes almost 600,000 people each year, killing the vast majority of those individuals, says a new report from the Institute of Medicine. Every year in the U.S., approximately 395,000 cases of cardiac arrest occur outside of a hospital setting, in which less than 6 percent survive. Approximately 200,000 cardiac arrests occur each year in hospitals, and 24 percent of those patients survive. Estimates suggest that cardiac arrest is the third leading cause of death in the U.S. behind cancer and heart disease. [More]
New IOM report calls for campaign to promote public education on CPR and AED use

New IOM report calls for campaign to promote public education on CPR and AED use

A new report released today from the Institute of Medicine calls for a campaign to promote public education and training opportunities to reduce barriers to the provision of bystander CPR and defibrillation. [More]
Implementation of public health strategies can improve survival rates of cardiac arrest in US

Implementation of public health strategies can improve survival rates of cardiac arrest in US

The Institute of Medicine Committee on the Treatment of Cardiac Arrest is announcing results of a new report that examines current statistics and survival rates of cardiac arrest in the United States, assesses evidence on existing lifesaving therapies, and recommends public health strategies that – if implemented – will improve cardiac arrest survival rates. Additionally, the report explores cardiopulmonary resuscitation (CPR) and the use of [More]
ProfNet network experts available to discuss timely issues in your coverage area

ProfNet network experts available to discuss timely issues in your coverage area

Below are experts from the ProfNet network that are available to discuss timely issues in your coverage area. You can also submit a query to the hundreds of thousands of experts in our network – it's easy and free! [More]
Life-saving defibrillators are grossly underutilized, shows study

Life-saving defibrillators are grossly underutilized, shows study

Heart attack patients age 65 and older who have reduced heart function might still benefit from implanted defibrillators, according to a Duke Medicine study published in the Journal of the American Medical Association. [More]
The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

The Lancet Oncology publishes results of CYRAMZA (ramucirumab) Phase III trial for HCC treatment

Eli Lilly and Company announced that The Lancet Oncology has published results of the Phase III REACH trial that evaluated CYRAMZA (ramucirumab) as a second-line treatment for people with hepatocellular carcinoma (HCC), also known as liver cancer. While the REACH trial's primary endpoint of overall survival favored the CYRAMZA arm, it was not statistically significant. [More]
Early CPR doubles chance of survival for patients suffering from cardiac arrest

Early CPR doubles chance of survival for patients suffering from cardiac arrest

A team of Swedish researchers finds that early cardiopulmonary resuscitation more than doubles the chance of survival for patients suffering out-of-hospital cardiac arrest. The percentage of patients who receive life-saving resuscitation has also increased substantially thanks to so-called SMS Lifesavers. [More]
Rapid cooling procedures prior to catheterization reduce extent of myocardial infarction

Rapid cooling procedures prior to catheterization reduce extent of myocardial infarction

After an acute myocardial infarction, patients treated with rapid lowering of body temperature by combined cold saline infusion and endovascular cooling had less heart muscle damage and reduced incidence of heart failure. Therapeutic hypothermia was especially protective against heart muscle damage in patients with a large area of myocardium at risk according to an analysis of two clinical trials published in Therapeutic Hypothermia and Temperature Management, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. [More]
Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen starts Phase 3 study assessing the benefit of Kyprolis in patients with relapsed/refractory multiple myeloma

Amgen today announced the initiation of the ARROW trial, a global Phase 3 study evaluating the benefit of Kyprolis® (carfilzomib) for Injection administered once-weekly with dexamethasone versus the current U.S. Food and Drug Administration (FDA) approved twice-weekly administration schedule in patients with relapsed and refractory multiple myeloma who have received prior treatment with bortezomib and an immunomodulatory agent (IMiD). [More]
Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Heart failure patient spearheads Heather Cartwright Inherited Cardiomyopathy and Arrhythmia Project

Led by internationally-recognized cardiologists who are leaders in their field, the Peter Munk Cardiac Centre today announces the creation of an initiative to break ground in the cause, treatment and ongoing care of patients with an inherited, irregular heartbeat triggered by a rare cardiac structural condition. [More]
Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen to present clinical data on multiple blood cancer treatments at EHA 2015

Amgen today announced that it will present data from multiple Kyprolis (carfilzomib) for Injection, BLINCYTO (blinatumomab), oprozomib and Nplate (romiplostim)‎ studies at the 20th Congress of the European Hematology Association taking place in Vienna, June 11 - 14, 2015. [More]
New hope for patients suffering from most severe forms of anorexia nervosa

New hope for patients suffering from most severe forms of anorexia nervosa

Anorexia Nervosa has the highest mortality rate of any mental illness. In its most severe form, victims face a devastating 4,500% increased risk for death. In the wake of the recent national attention on the limited treatment options available for these extreme cases, it is important for sufferers to know that help is available. [More]
Elderly cardiac patients receive less evidence-based treatment compared to younger patients

Elderly cardiac patients receive less evidence-based treatment compared to younger patients

People in their 80s and 90s are more likely to develop acute coronary syndrome than their younger counterparts. Despite this, they receive less therapy and diagnostic procedures. A doctoral thesis at Sahlgrenska Academy has explored the topic. [More]

Powerheart G5 AED era arrives in the U.S. and Canada

Cardiac Science, an Opto Circuits group company and a global leader in AEDs, is proud to announce today that the Powerheart G5 AED era has arrived in the United States and Canada, representing both a technological milestone in the AED industry and the company's latest tool in fighting the world's No. 1 killer: sudden cardiac arrest (SCA). [More]
Study: Therapeutic hypothermia offers little neurological benefit to children with cardiac arrest

Study: Therapeutic hypothermia offers little neurological benefit to children with cardiac arrest

A new, randomized clinical study co-authored by Cohen Children's Medical Center's chair of pediatrics says there is little neurological benefit to using therapeutic hypothermia to lower a child's core temperature after an out-of-hospital cardiac arrest. [More]
Emergency body cooling, therapeutic hypothermia yield similar outcomes for children with cardiac arrest

Emergency body cooling, therapeutic hypothermia yield similar outcomes for children with cardiac arrest

A large-scale, multicenter study has shown that emergency body cooling does not improve survival rates or reduce brain injury in infants and children with out-of-hospital cardiac arrest more than normal temperature control. [More]
Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Lilly receives fourth FDA approval for CYRAMZA (ramucirumab)

Eli Lilly and Company has received its fourth U.S. Food and Drug Administration approval for CYRAMZA (ramucirumab). CYRAMZA (ramucirumab injection 10 mg/mL solution) is now also indicated in combination with FOLFIRI (irinotecan, folinic acid, and 5-fluorouracil) chemotherapy for the treatment of patients with metastatic colorectal cancer (mCRC) with disease progression on or after prior therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine. [More]
Ultrasound settings can change beat frequency of cardiac cells

Ultrasound settings can change beat frequency of cardiac cells

Ultrasound—the technology used for sonograms and examining the heart—can increase the rate at which heart cells beat, researchers from Drexel University report. [More]
Majority of patients who survive cardiac arrest experience cognitive problems

Majority of patients who survive cardiac arrest experience cognitive problems

Half of all patients who survive a cardiac arrest experience problems with cognitive functions such as memory and attention. [More]
Administration of selenide protects heart tissue post cardiac arrest, shows study

Administration of selenide protects heart tissue post cardiac arrest, shows study

Damage to heart muscle from insufficient blood supply during cardiac arrest and reperfusion injury after blood flow is restored can be reduced by nearly 90 percent if selenide, a form of the essential nutrient selenium, is administered intravenously in the wake of the attack, according to a new preclinical study by researchers at Fred Hutchinson Cancer Research Center. [More]
Advertisement
Advertisement